Comment: Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data-Reference-Cited by-同舟云学术

Comment: Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data

Published:2020-02-28 Issue:9 Volume:54 Page:939-940
ISSN:1060-0280
Container-title:Annals of Pharmacotherapy
language:en
Short-container-title:Ann Pharmacother

Author:

Cumhur Cure Medine^ORCID,Cure Erkan^ORCID

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Link

http://journals.sagepub.com/doi/pdf/10.1177/1060028020910204

Reference5 articles.

1. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data

2. Comment on: “High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment”

3. Mitochondrial redox state in the critically ill

4. High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment

5. Lactate, a Neglected Factor for Diabetes and Cancer Interaction

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW;Military Medical Science Letters;2022-06-03

2. The coronavirus disease 2019 and effect on liver function: a hidden and vital interaction beyond the respiratory system;Reviews in Medical Microbiology;2021-01-18

3. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2020-07

4. Comment on “Subtype‐Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study”;The Journal of Clinical Pharmacology;2020-05-14